These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

194 related items for PubMed ID: 37397366

  • 1. Rac and Cdc42 inhibitors reduce macrophage function in breast cancer preclinical models.
    Torres-Sanchez A, Rivera-Robles M, Castillo-Pichardo L, Martínez-Ferrer M, Dorta-Estremera SM, Dharmawardhane S.
    Front Oncol; 2023; 13():1152458. PubMed ID: 37397366
    [Abstract] [Full Text] [Related]

  • 2. Characterization of Novel Derivatives of MBQ-167, an inhibitor of the GTP-binding proteins Rac/Cdc42.
    Medina JI, Cruz-Collazo A, Del Mar Maldonado M, Gascot TM, Borrero-Garcia LD, Cooke M, Kazanietz MG, O'Farril EH, Vlaar CP, Dharmawardhane S.
    Cancer Res Commun; 2022 Dec; 2(12):1711-1726. PubMed ID: 36861094
    [Abstract] [Full Text] [Related]

  • 3. Characterization of a Dual Rac/Cdc42 Inhibitor MBQ-167 in Metastatic Cancer.
    Humphries-Bickley T, Castillo-Pichardo L, Hernandez-O'Farrill E, Borrero-Garcia LD, Forestier-Roman I, Gerena Y, Blanco M, Rivera-Robles MJ, Rodriguez-Medina JR, Cubano LA, Vlaar CP, Dharmawardhane S.
    Mol Cancer Ther; 2017 May; 16(5):805-818. PubMed ID: 28450422
    [Abstract] [Full Text] [Related]

  • 4. Characterization of EHop-016, novel small molecule inhibitor of Rac GTPase.
    Montalvo-Ortiz BL, Castillo-Pichardo L, Hernández E, Humphries-Bickley T, De la Mota-Peynado A, Cubano LA, Vlaar CP, Dharmawardhane S.
    J Biol Chem; 2012 Apr 13; 287(16):13228-38. PubMed ID: 22383527
    [Abstract] [Full Text] [Related]

  • 5. Development of EHop-016: a small molecule inhibitor of Rac.
    Dharmawardhane S, Hernandez E, Vlaar C.
    Enzymes; 2013 Apr 13; 33 Pt A(Pt A):117-46. PubMed ID: 25033803
    [Abstract] [Full Text] [Related]

  • 6. The Rac Inhibitor EHop-016 Inhibits Mammary Tumor Growth and Metastasis in a Nude Mouse Model.
    Castillo-Pichardo L, Humphries-Bickley T, De La Parra C, Forestier-Roman I, Martinez-Ferrer M, Hernandez E, Vlaar C, Ferrer-Acosta Y, Washington AV, Cubano LA, Rodriguez-Orengo J, Dharmawardhane S.
    Transl Oncol; 2014 Oct 13; 7(5):546-55. PubMed ID: 25389450
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and delivery strategies of the dual Rac/Cdc42 inhibitor MBQ-167 in HER2 overexpressing breast cancer.
    Velázquez-Vega LE, Rivera-Robles M, Sánchez-Álvarez AO, Vivas-Mejía PE, Aponte-Reyes M, Cruz-Collazo AM, Grafals-Ruiz N, Dorta-Estremera S, Hernández-O'Farrill E, Vlaar CP, Dharmawardhane S.
    Transl Oncol; 2024 Jun 13; 44():101928. PubMed ID: 38489873
    [Abstract] [Full Text] [Related]

  • 8. Efficacy of Rac and Cdc42 Inhibitor MBQ-167 in Triple-negative Breast Cancer.
    Cruz-Collazo A, Ruiz-Calderon JF, Picon H, Borrero-Garcia LD, Lopez I, Castillo-Pichardo L, Del Mar Maldonado M, Duconge J, Medina JI, Bayro MJ, Hernández-O'Farrill E, Vlaar CP, Dharmawardhane S.
    Mol Cancer Ther; 2021 Dec 13; 20(12):2420-2432. PubMed ID: 34607932
    [Abstract] [Full Text] [Related]

  • 9. The Rac inhibitor HV-107 as a potential therapeutic for metastatic breast cancer.
    Crespo GV, Ortiz J, O'Farrill EH, Vlaar CP, Inyushin M, Kucheryavykh Y, Kucheryavykh L.
    Mol Med; 2023 Jun 14; 29(1):75. PubMed ID: 37316799
    [Abstract] [Full Text] [Related]

  • 10. Targeting Cdc42 with the anticancer compound MBQ-167 inhibits cell polarity and growth in the budding yeast S. cerevisiae.
    Rivera-Robles MJ, Medina-Velázquez J, Asencio-Torres GM, González-Crespo S, Rymond BC, Rodríguez-Medina J, Dharmawardhane S.
    Small GTPases; 2020 Nov 14; 11(6):430-440. PubMed ID: 29969362
    [Abstract] [Full Text] [Related]

  • 11. Plexin-B2 negatively regulates macrophage motility, Rac, and Cdc42 activation.
    Roney KE, O'Connor BP, Wen H, Holl EK, Guthrie EH, Davis BK, Jones SW, Jha S, Sharek L, Garcia-Mata R, Bear JE, Ting JP.
    PLoS One; 2011 Nov 14; 6(9):e24795. PubMed ID: 21966369
    [Abstract] [Full Text] [Related]

  • 12. Visualization and quantification of in vivo homing kinetics of myeloid-derived suppressor cells in primary and metastatic cancer.
    Hoffmann SHL, Reck DI, Maurer A, Fehrenbacher B, Sceneay JE, Poxleitner M, Öz HH, Ehrlichmann W, Reischl G, Fuchs K, Schaller M, Hartl D, Kneilling M, Möller A, Pichler BJ, Griessinger CM.
    Theranostics; 2019 Nov 14; 9(20):5869-5885. PubMed ID: 31534525
    [Abstract] [Full Text] [Related]

  • 13. Targeting Rac and Cdc42 GEFs in Metastatic Cancer.
    Maldonado MDM, Medina JI, Velazquez L, Dharmawardhane S.
    Front Cell Dev Biol; 2020 Nov 14; 8():201. PubMed ID: 32322580
    [Abstract] [Full Text] [Related]

  • 14. Pharmacokinetics of Rac inhibitor EHop-016 in mice by ultra-performance liquid chromatography tandem mass spectrometry.
    Humphries-Bickley T, Castillo-Pichardo L, Corujo-Carro F, Duconge J, Hernandez-O'Farrill E, Vlaar C, Rodriguez-Orengo JF, Cubano L, Dharmawardhane S.
    J Chromatogr B Analyt Technol Biomed Life Sci; 2015 Feb 15; 981-982():19-26. PubMed ID: 25594952
    [Abstract] [Full Text] [Related]

  • 15. Rac1 and Rac3 isoform activation is involved in the invasive and metastatic phenotype of human breast cancer cells.
    Baugher PJ, Krishnamoorthy L, Price JE, Dharmawardhane SF.
    Breast Cancer Res; 2005 Feb 15; 7(6):R965-74. PubMed ID: 16280046
    [Abstract] [Full Text] [Related]

  • 16. Vav regulates activation of Rac but not Cdc42 during FcgammaR-mediated phagocytosis.
    Patel JC, Hall A, Caron E.
    Mol Biol Cell; 2002 Apr 15; 13(4):1215-26. PubMed ID: 11950933
    [Abstract] [Full Text] [Related]

  • 17. Rac inhibition as a novel therapeutic strategy for EGFR/HER2 targeted therapy resistant breast cancer.
    Borrero-García LD, Del Mar Maldonado M, Medina-Velázquez J, Troche-Torres AL, Velazquez L, Grafals-Ruiz N, Dharmawardhane S.
    BMC Cancer; 2021 Jun 01; 21(1):652. PubMed ID: 34074257
    [Abstract] [Full Text] [Related]

  • 18. A role for Cdc42 in macrophage chemotaxis.
    Allen WE, Zicha D, Ridley AJ, Jones GE.
    J Cell Biol; 1998 Jun 01; 141(5):1147-57. PubMed ID: 9606207
    [Abstract] [Full Text] [Related]

  • 19. Two distinct mTORC2-dependent pathways converge on Rac1 to drive breast cancer metastasis.
    Morrison Joly M, Williams MM, Hicks DJ, Jones B, Sanchez V, Young CD, Sarbassov DD, Muller WJ, Brantley-Sieders D, Cook RS.
    Breast Cancer Res; 2017 Jun 30; 19(1):74. PubMed ID: 28666462
    [Abstract] [Full Text] [Related]

  • 20. Targeting the crosstalk between cytokine-induced killer cells and myeloid-derived suppressor cells in hepatocellular carcinoma.
    Yu SJ, Ma C, Heinrich B, Brown ZJ, Sandhu M, Zhang Q, Fu Q, Agdashian D, Rosato U, Korangy F, Greten TF.
    J Hepatol; 2019 Mar 30; 70(3):449-457. PubMed ID: 30414862
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.